Context Therapeutics Investor Presentation Deck

Phase 1b/2 (ELONA Trial) - Designed to Evaluate Combination Efficacy and Tolerability · . - Indication: ER+,PR+,HER2- advanced or metastatic breast cancer Study: Phase 1b (n=12-28) / Phase 2 (n=45) Primary Endpoint: overall response rate (ORR) Secondary Endpoint: progression free survival (PFS), clinical benefit rate (CBR) Sites: US only, 16-19 sites Patient Population Prior therapy with CDK4/6 inhibitor required No prior chemotherapy in metastatic setting permitted ≥ 50% of patients will have ESR1 mutation ● 12 Context Therapeutics Inc. - Sept. 2022 Phase 1b M Dose escalation 12-28 patients Menarini Clinical Trial Collaboration • 4 cohorts Phase 2 . -45 patients

View entire presentation